NHS Data Firms Arcturis and Akrivia Merge for £140M to Take on Palantir

The Quick Take

• NHS patient data providers Arcturis and Akrivia are merging in a £140M deal to gain scale against Palantir.
• The deal targets the pharmaceuticals industry market for NHS patient data analytics.
• The merger is a direct competitive response to Palantir Technologies' growing dominance in UK health data.

Two major UK providers of NHS patient data analytics are combining in a £140 million merger, creating a scaled British alternative to the American data analytics giant Palantir Technologies. Arcturis and Akrivia serve pharmaceutical companies seeking clinical trial insights, drug discovery support, and real-world evidence generation from NHS's uniquely comprehensive longitudinal patient data. The NHS dataset is considered one of the world's most valuable health data assets, covering approximately 68 million patients across decades of continuous care records.

The strategic rationale is defensive scale-building. Palantir's Foundry platform has established deep relationships with NHS England, and its Federated Data Platform contract — worth hundreds of millions of pounds — has given it a structural advantage in processing NHS data. A merged Arcturis-Akrivia would have the combined revenue base, data access relationships, and product breadth to compete more credibly for pharmaceutical company contracts that currently default to Palantir's end-to-end capabilities.

Investors should watch the Competition and Markets Authority review of the merger, as both companies serve overlapping NHS data markets and consolidation may raise concerns about data access concentration. The broader NHS data commercialisation policy direction is a key variable — if NHS England broadens access frameworks, more competitors could emerge and dilute the merged entity's pricing power. Palantir's stock reaction to the announcement will signal market assessment of the competitive threat.

Synthesized from 1 source.